Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/10/23
End: 09/29/27
Due: 09/29/28
Phase: N/A
Priority: Normal
Start: 04/13/22
End: 08/16/27
Due: 08/16/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05997615 | Amunix, a Sanofi Company | user2@example.com | None | 2023-08-10 | 2027-09-29 | 2028-09-29 | - | - | 2025-07-14 |
| To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | NCT05356741 | Amunix, a Sanofi Company | user2@example.com | None | 2022-04-13 | 2027-08-16 | 2028-08-16 | - | - | 2025-07-14 |